JP2002506044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002506044A5 JP2002506044A5 JP2000535362A JP2000535362A JP2002506044A5 JP 2002506044 A5 JP2002506044 A5 JP 2002506044A5 JP 2000535362 A JP2000535362 A JP 2000535362A JP 2000535362 A JP2000535362 A JP 2000535362A JP 2002506044 A5 JP2002506044 A5 JP 2002506044A5
- Authority
- JP
- Japan
- Prior art keywords
- follistatin
- functional fragment
- disease
- composition according
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000016970 Follistatin Human genes 0.000 description 18
- 108010014612 Follistatin Proteins 0.000 description 18
- 239000012634 fragment Substances 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 201000010099 disease Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 201000006938 muscular dystrophy Diseases 0.000 description 10
- 101000931668 Homo sapiens Follistatin Proteins 0.000 description 9
- 102000050536 human FST Human genes 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 8
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 102000001690 Factor VIII Human genes 0.000 description 4
- 108010054218 Factor VIII Proteins 0.000 description 4
- 208000010316 Myotonia congenita Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000036244 malformation Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000009693 chronic damage Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000029323 Congenital myotonia Diseases 0.000 description 2
- 208000001441 Familial Periodic Paralyses Diseases 0.000 description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010028424 Myasthenic syndrome Diseases 0.000 description 2
- 206010028629 Myoglobinuria Diseases 0.000 description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 201000006793 Walker-Warburg syndrome Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000011474 congenital myopathy Diseases 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 206010016208 familial periodic paralysis Diseases 0.000 description 2
- 208000025855 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Diseases 0.000 description 2
- 230000036473 myasthenia Effects 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 206010030875 ophthalmoplegia Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/037,118 | 1998-03-09 | ||
| US09/037,118 US6004937A (en) | 1998-03-09 | 1998-03-09 | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| PCT/US1999/004003 WO1999045949A2 (en) | 1998-03-09 | 1999-02-24 | Use of follistatin to modulate gdf-8 and bmp-11 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009222855A Division JP2010043099A (ja) | 1998-03-09 | 2009-09-28 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
| JP2010061242A Division JP2010195794A (ja) | 1998-03-09 | 2010-03-17 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002506044A JP2002506044A (ja) | 2002-02-26 |
| JP2002506044A5 true JP2002506044A5 (enExample) | 2006-07-06 |
Family
ID=21892528
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000535362A Withdrawn JP2002506044A (ja) | 1998-03-09 | 1999-02-24 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
| JP2009222855A Pending JP2010043099A (ja) | 1998-03-09 | 2009-09-28 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
| JP2010061242A Pending JP2010195794A (ja) | 1998-03-09 | 2010-03-17 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009222855A Pending JP2010043099A (ja) | 1998-03-09 | 2009-09-28 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
| JP2010061242A Pending JP2010195794A (ja) | 1998-03-09 | 2010-03-17 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6004937A (enExample) |
| EP (3) | EP2347760A3 (enExample) |
| JP (3) | JP2002506044A (enExample) |
| AT (1) | ATE256475T1 (enExample) |
| AU (1) | AU759838B2 (enExample) |
| CA (1) | CA2322716C (enExample) |
| DE (1) | DE69913665T2 (enExample) |
| DK (1) | DK1061940T3 (enExample) |
| ES (1) | ES2212533T3 (enExample) |
| PT (1) | PT1061940E (enExample) |
| WO (1) | WO1999045949A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| DE69233022T2 (de) | 1991-11-04 | 2004-02-12 | Genetics Institute, LLC, Cambridge | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| EP2272959A1 (en) * | 1993-05-12 | 2011-01-12 | Genetics Institute, LLC | BMP-11 compositions |
| US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| ES2255059T3 (es) | 1993-12-07 | 2006-06-16 | Genetics Institute, Llc | Bmp-12, bmp-13 y composiciones suyas inductoras de tendon. |
| US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
| WO2001009368A1 (en) * | 1999-07-30 | 2001-02-08 | The General Hospital Corporation | Follistatin antagonists |
| ATE271886T1 (de) | 1999-10-15 | 2004-08-15 | Inst Genetics Llc | Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine |
| EP1790726B1 (en) * | 2001-02-08 | 2013-07-03 | Wyeth LLC | Modified and stabilized GDF propeptides and uses thereof |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| KR100420798B1 (ko) * | 2001-02-10 | 2004-03-02 | (주)알에이싸이언스 | 펩타이드 벡터 |
| ATE393573T1 (de) | 2001-06-01 | 2008-05-15 | Wyeth Corp | Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| US20030103959A1 (en) * | 2001-06-22 | 2003-06-05 | Hughes Paul E. | Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US6798160B2 (en) * | 2001-11-02 | 2004-09-28 | Honda Giken Kogyo Kabushiki Kaisha | Electric working machine |
| US20030144203A1 (en) * | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
| GB2385052A (en) * | 2002-02-05 | 2003-08-13 | Leuven K U Res & Dev | Treatment of spondyloarthropathies |
| WO2003072715A2 (en) * | 2002-02-21 | 2003-09-04 | Wyeth | Gasp1: a follistatin domain containing protein |
| AU2003216345A1 (en) * | 2002-02-21 | 2003-09-09 | Wyeth | Follistatin domain containing proteins |
| BR0314270A (pt) * | 2002-09-16 | 2005-08-02 | Univ Johns Hopkins | Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US20050192225A1 (en) * | 2002-12-18 | 2005-09-01 | Bowen Richard L. | Methods for treating Parkinson's disease |
| MXPA05012965A (es) * | 2003-06-02 | 2006-03-09 | Wyeth Corp | Uso de inhibidores de miostatina (gdf8) en conjuncion con corticoesteroides para el tratamiento de desordenes neuromusculares y composiciones farmaceuticas para ello. |
| NZ546438A (en) | 2003-09-12 | 2010-07-30 | Wyeth Corp | Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins |
| UA93855C2 (ru) * | 2003-12-31 | 2011-03-25 | Шеринг-Плау Лтд. | Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе |
| JP4688483B2 (ja) * | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| CA2575563A1 (en) * | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| JP2008526201A (ja) | 2004-12-30 | 2008-07-24 | シェーリング−プラウ・リミテッド | 中和エピトープベースの成長増強ワクチン |
| WO2006081379A1 (en) * | 2005-01-26 | 2006-08-03 | Wyeth | Use of sfrps as markers of bmp activity |
| NZ538097A (en) * | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| WO2006107611A2 (en) * | 2005-03-23 | 2006-10-12 | Wyeth | Detection of an immune response to gdf-8 modulating agents |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| US8236751B2 (en) * | 2007-03-07 | 2012-08-07 | The Johns Hopkins University | Methods of increasing muscle mass using follistatin-like related gene (FLRG) |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| PT2170396T (pt) | 2007-08-03 | 2017-03-31 | Summit Corp Plc | Combinação de fármacos para o tratamento da distrofia muscular de duchenne |
| CA2729096C (en) | 2008-06-26 | 2020-04-28 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| AU2013313282B2 (en) | 2012-08-01 | 2018-02-01 | Ikaika Therapeutics, Llc | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4) |
| MA51075A (fr) | 2014-06-04 | 2020-10-14 | Acceleron Pharma Inc | Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| US9975934B2 (en) | 2015-03-26 | 2018-05-22 | Acceleron Pharma Inc. | Follistatin-related fusion proteins |
| WO2019046903A1 (en) * | 2017-09-08 | 2019-03-14 | Baker Heart and Diabetes Institute | THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT |
| AU2019406214A1 (en) | 2018-12-21 | 2021-08-05 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041538A (en) * | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
| US5171579A (en) * | 1991-10-11 | 1992-12-15 | Genetics Institute, Inc. | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
| DE69432815T2 (de) * | 1993-03-19 | 2003-12-11 | The Johns Hopkins University School Of Medicine, Baltimore | Wachstumsfaktor-8 |
| EP2272959A1 (en) * | 1993-05-12 | 2011-01-12 | Genetics Institute, LLC | BMP-11 compositions |
| WO1995010611A1 (en) * | 1993-10-14 | 1995-04-20 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
| US5545616A (en) * | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
| US6281332B1 (en) * | 1994-12-02 | 2001-08-28 | The Johns Hopkins University School Of Medicine | Hedgehog-derived polypeptides |
| GB2306481A (en) * | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
| US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
-
1998
- 1998-03-09 US US09/037,118 patent/US6004937A/en not_active Expired - Lifetime
-
1999
- 1999-02-24 WO PCT/US1999/004003 patent/WO1999045949A2/en not_active Ceased
- 1999-02-24 AU AU27854/99A patent/AU759838B2/en not_active Ceased
- 1999-02-24 DK DK99908416T patent/DK1061940T3/da active
- 1999-02-24 DE DE69913665T patent/DE69913665T2/de not_active Expired - Lifetime
- 1999-02-24 PT PT99908416T patent/PT1061940E/pt unknown
- 1999-02-24 EP EP10185247A patent/EP2347760A3/en not_active Withdrawn
- 1999-02-24 ES ES99908416T patent/ES2212533T3/es not_active Expired - Lifetime
- 1999-02-24 JP JP2000535362A patent/JP2002506044A/ja not_active Withdrawn
- 1999-02-24 CA CA2322716A patent/CA2322716C/en not_active Expired - Fee Related
- 1999-02-24 EP EP99908416A patent/EP1061940B1/en not_active Expired - Lifetime
- 1999-02-24 EP EP03028901A patent/EP1444985A3/en not_active Withdrawn
- 1999-02-24 AT AT99908416T patent/ATE256475T1/de active
-
2009
- 2009-09-28 JP JP2009222855A patent/JP2010043099A/ja active Pending
-
2010
- 2010-03-17 JP JP2010061242A patent/JP2010195794A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002506044A5 (enExample) | ||
| Carlstedt et al. | Functional recovery in primates with brachial plexus injury after spinal cord implantation of avulsed ventral roots. | |
| Brustein et al. | Recovery of locomotion after ventral and ventrolateral spinal lesions in the cat. II. Effects of noradrenergic and serotoninergic drugs | |
| Bennett et al. | Spastic long-lasting reflexes in the awake rat after sacral spinal cord injury | |
| Barbeau et al. | Enhancement of locomotor recovery following spinal cord injury | |
| Spaić et al. | Microsurgical DREZotomy for pain of spinal cord and Cauda equina injury origin: clinical characteristics of pain and implications for surgery in a series of 26 patients | |
| Gordon et al. | Experimental strategies to promote functional recovery after peripheral nerve injuries | |
| Danda et al. | Comparison of gap arthroplasty with and without a temporalis muscle flap for the treatment of ankylosis | |
| ATE256475T1 (de) | Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten | |
| EP3746126B1 (en) | Methods and compositions for treating sleep apnea or simple snoring | |
| Dietz et al. | Recovery from spinal cord injury—underlying mechanisms and efficacy of rehabilitation | |
| Sood et al. | Treatment of painful neuromas of the hand and wrist by relocation into the pronator quadratus muscle | |
| CA2154103A1 (en) | Treatment of Mucous Membrane Disease, Trauma or Condition and for the Relief of Pain | |
| Nishimoto et al. | Transcutaneous carbon dioxide application with hydrogel prevents muscle atrophy in a rat sciatic nerve crush model | |
| Butler et al. | Bupivacaine and Kaltostat reduces post-operative donor site pain | |
| Saboisky et al. | Potential therapeutic targets in obstructive sleep apnoea | |
| Sériès et al. | Corticomotor control of the genioglossus in awake OSAS patients: a transcranial magnetic stimulation study | |
| Carlstedt | Approaches permitting and enhancing motoneuron regeneration after spinal cord, ventral root, plexus and peripheral nerve injuries | |
| Vazquez et al. | The effects of sensory stimulation on REM sleep duration | |
| RU2120289C1 (ru) | Способ лечения больных с неврологическими проявлениями остеохондроза позвоночника | |
| Hayakawa et al. | Nerve growth factor prevention of aged-rat sympathetic neuron injury by cisplatin, vincristine and taxol–in vitro explant study | |
| SE1550338A1 (en) | A composition for use in the treatment of intervertebral misalignment | |
| de la Plaza et al. | Can some facial rejuvenation techniques cause latrogenia? | |
| AU6418296A (en) | Aromatic acid diamides with antigastrin activity, a method for their preparation and their pharmaceutical use | |
| Bruetsch et al. | THE PARKINSONIAN SYNDROME DUE TO TRAUMA*: A Clinico-Anatomical Study of A Case |